WeQual: Eight Exceptional Women Executives Honoured in EMEA Diversity Awards
15.12.2020 18:17:00 EET | Business Wire | Press release
Eight businesswomen holding prominent executive roles in leading companies in Europe, the Middle East and Africa have been named as winners in the annual WeQual Awards (www.wequal.com/awards).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005796/en/
WeQual EMEA 2020 - Winners (Photo: Business Wire)
WeQual identifies and recognises world-class women executives, one level below the group C-suite, and is designed to promote diversity and gender equality within the group executive committees of EMEA’s largest companies.
The eight winners were selected from a shortlist of 24 finalists. The successful award holders are employed in Aryzta, Bayer’s Consumer Health Division, Bureau Veritas, Fresenius Medical Care, Ooredoo Qatar, Sodexo, Standard Chartered Bank and Unilever.
Katie Litchfield, Founder and CEO of WeQual, says: “WeQual identifies already successful senior women who are qualified to be appointed to the group C-suite. Our mission is to tackle the slow progress in appointing diverse women to executive roles and highlight successes where they occur.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the group C-suite, so it is important to champion gender equality at the top.”
The awards come at an important time for women in business. The global Covid-19 pandemic is in danger of pushing back opportunities for women to be appointed to the most senior positions. “The fact that we are able to celebrate the achievements of these women in major companies at this time sets a shining example to others,” says Katie Litchfield.
The winners are:
− Bola Adesola: Senior Vice-Chairman, Africa, Standard Chartered Bank, Nigeria. Head of Region Category.
− Dr Cora Koppe-Stahrenberg: Executive Vice President, Global Head of Human Resources, Fresenius Medical Care, Germany. People Excellence Category.
− Munera AL-Dosari: Chief Strategy Officer, Ooredoo Qatar. Strategy Development Category.
− Patricia Amaro: Digital Hub and E-commerce Director, Unilever, Spain. Digital Impact Category.
− Patricia Corsi: Global Chief Marketing and Digital Officer, Bayer’s Consumer Health Division, Switzerland. Brand Innovation Category.
− Nathalie Pousin: Chief Financial Officer, France, Africa, GSIT, Bureau Veritas, France. Finance Category.
− Petra Melander: EMEA Account Director, Sodexo, Finland. Commercial Performance Category.
− Rebeca Navarro: Chief Transformation Officer for Europe and Head of Procurement, Aryzta, Switzerland. Transformational Leadership Category.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive and Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
To choose the winners, eight executive interviewers held 30-minute interviews with the three finalists in each category before each choosing a category winner. The judges were:
− Sir Ian Cheshire, Chairman, Barclays UK
− Viswas Raghavan, CEO EMEA, J.P. Morgan
− Warren East, CEO, Rolls-Royce
− Dame Inga Beale, Chairperson, Mediclinic
− Chris O'Shea, CEO, Centrica
− Ron Kalifa OBE, Chairman, Network International
− Tamara Box, Managing Partner EME, Reed Smith LLP
− Tulsi Naidu, CEO, Zurich Insurance Company UK
All the 24 award finalists have been given access to a range of WeQual support services and networks designed to help them make the step up to the group executive level. A quarter of WeQual award winners in the UK and USA have since been promoted to the global executive committees of FTSE and Fortune 500 companies. There are now 96 senior women involved with WeQual globally.
(Ends)
Notes to editors
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Group Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they deserve to be appointed to the Group Executive Committee.
- LinkedIn: https://www.linkedin.com/company/wequal-awards
- Twitter: https://twitter.com/WeQualGlobal
- YouTube: https://www.youtube.com/channel/UCBpixTLeUsQVjwrivAP9-KA
- Facebook: https://www.facebook.com/WeQualAwards
- Instagram: https://www.instagram.com/wequalglobal
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005796/en/
Contact information
Katie Litchfield
katie@wequal.com
Mobile: + 44 7796 147466
UK office: +44 20 3290 3389
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
